AM679 - CAS 1206880-66-1
Catalog number:
1206880-66-1
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C40H44N4O5S
Molecular Weight:
692.87
COA:
Inquire
Targets:
FLAP
Description:
AM679 is a drug which acts as a selective inhibitor of 5-Lipoxygenase-activating protein (FLAP). This protein is involved in the production of cysteinyl leukotrienes which are involved in inflammation, and AM679 has anti-inflammatory effects in animal studies. AM679 also showed potent inhibition of leukotrienes in human blood and in a rodent bronchoalvelolar lavage (BAL) challenge model. Research showed AM679 reduces inflammation in the respiratory syncytial virus-infected mouse eye.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
AM-679; AM 679
MSDS:
Inquire
1.A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye.
Musiyenko A1, Correa L, Stock N, Hutchinson JH, Lorrain DS, Bain G, Evans JF, Barik S. Clin Vaccine Immunol. 2009 Nov;16(11):1654-9. doi: 10.1128/CVI.00220-09. Epub 2009 Sep 16.
Respiratory syncytial virus (RSV) is an important cause of viral respiratory disease in children, and RSV bronchiolitis has been associated with the development of asthma in childhood. RSV spreads from the eye and nose to the human respiratory tract. Correlative studies of humans and direct infection studies of BALB/c mice have established the eye as a significant pathway of entry of RSV to the lung. At the same time, RSV infection of the eye produces symptoms resembling allergic conjunctivitis. Cysteinyl leukotrienes (CysLTs) are known promoters of allergy and inflammation, and the first step in their biogenesis from arachidonic acid is catalyzed by 5-lipoxygenase (5-LO) in concert with the 5-LO-activating protein (FLAP). We have recently developed a novel compound, AM679, which is a topically applied and potent inhibitor of FLAP. Here we show with the BALB/c mouse eye RSV infection model that AM679 markedly reduced the RSV-driven ocular pathology as well as the synthesis of CysLTs in the eye.
2.Identification of two cannabimimetic compounds WIN48098 and AM679 in illegal products.
Gregori A1, Damiano F, Bonavia M, Mileo V, Varani F, Monfreda M. Sci Justice. 2013 Sep;53(3):286-92. doi: 10.1016/j.scijus.2012.10.002. Epub 2012 Nov 9.
Two synthetic cannabinoids have been identified, during a survey, as new adulterants; they might have been intended to be used as ingredients for smart drugs. The characterization of these compounds has been made by gas chromatography-mass spectrometry (GC-MS), Orbitrap high resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR), leading to the identification of WIN48098, a compound disclosed as a new adulterant in herbal and powder products, and AM679, identified in Italy for the first time. Taking into account the high number of synthetic cannabinoids seized during the last year in Italy, how quickly they appear on the illegal market and the rapidity required for analytical results, a method was developed for the simultaneous quantitation of several synthetic cannabinoids, using gas chromatography-flame ionization detection (GC-FID).
3.5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (Stock N1, Baccei C, Bain G, Broadhead A, Chapman C, Darlington J, King C, Lee C, Li Y, Lorrain DS, Prodanovich P, Rong H, Santini A, Zunic J, Evans JF, Hutchinson JH, Prasit P. Bioorg Med Chem Lett. 2010 Jan 1;20(1):213-7. doi: 10.1016/j.bmcl.2009.10.131. Epub 2009 Oct 31.
A series of potent 5-lipoxygenase-activating protein (FLAP) inhibitors are herein described. SAR studies focused on the discovery of novel alicyclic moieties appended to an indole core to optimize potency, physical properties and off-target activities. Subsequent SAR on the N-benzyl substituent of the indole led to the discovery of compound 39 (AM679) which showed potent inhibition of leukotrienes in human blood and in a rodent bronchoalvelolar lavage (BAL) challenge model.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related FLAP Products


CAS 128253-31-6 BAY-X-1005

BAY-X-1005
(CAS: 128253-31-6)

BAY-X 1005 is a potent and selective FLAP (5-lipoxygenase-activating protein) inhibitor. BAY-X 1005 is also a selective inhibitor of leukotriene synthesis. BAY-...

CAS 1206880-66-1 AM679

AM679
(CAS: 1206880-66-1)

AM679 is a drug which acts as a selective inhibitor of 5-Lipoxygenase-activating protein (FLAP). This protein is involved in the production of cysteinyl leukotr...

CAS 136668-42-3 MK-0591

MK-0591
(CAS: 136668-42-3)

Quiflapon is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. Also, Quifla...

CAS 147030-01-1 MK591

MK591
(CAS: 147030-01-1)

Quiflapon is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. Also, Quifla...

CAS 936350-00-4 GSK2190915

GSK2190915
(CAS: 936350-00-4)

GSK2190915 is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor. It exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. It a...

CAS 1196070-26-4 GSK2190915 sodium salt

GSK2190915 sodium salt
(CAS: 1196070-26-4)

GSK2190915(AM-803; Fiboflapon) sodium salt is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM.

Chemical Structure

CAS 1206880-66-1 AM679

Quick Inquiry

Verification code

Featured Items